Gilead Sciences to acquire biotechnology company Arcellx.

Gilead Sciences announced on February 23 that it has reached a final agreement to acquire the biotechnology company Arcellx for $115 per share in cash, with an additional $5 per share in contingent value rights. The implied equity value of the acquisition agreement is $7.8 billion, to be paid upon completion of the transaction.